search results for

refine results

sort by


result type


Press Releases

Fire Wells Fargo CEO Stumpf, says congressman who went off at hearing

Wells Fargo needs a new CEO because John Stumpf can't get the banking giant back on track, House Financial Services member Gregory Meeks tells CNBC.


Cramer: This entire group is under fire right now

Jim Cramer rattles off his take on caller favorite stocks, including this stock that's part of a group that can't stand the heat.


NYC reacts to the debate: 'That was a dumpster fire'

CNBC went downtown to see how New York City workers felt about Monday night's first presidential debate.


Impeachment? Invasion? No big deal for these two hot stock markets

The Brazil and Russian economies have been crushed by oil prices, political corruption and geopolitical risks. So why are their stocks on fire?


Mylan, Wells Fargo CEOs unprepared, not contrite, Yale's Jeff Sonnenfeld says

Corporate America saw two of its CEOs under fire this week on Capitol Hill, and management experts said their performances left a lot to be desired.


Tobacco stocks on fire despite proposed cigarette tax hikes

Tobacco stocks have been lighting up in the past year despite ongoing anti-smoking campaigns and proposed cigarette tax hikes in several states.


Mylan CEO Heather Bresch draws fire over private jet use

The optics of Mylan CEO Heather Bresch's use of a private jet to fly to her testimony before Congress may not have been ideal.


CEOs under fire on Capitol Hill: Expert

Mary Uhl-Bien, Neeley School of Business, comments on two high-profile hearings this week in Congress; Wells Fargo CEO John Stumpf about the banks account scandal, and Mylan CEO Heather Bresch on the huge price hike in EpiPens.


Cramer: Don't sweat it, this stock goes to $200 in the long run

Jim Cramer rattles off his take on caller favorite stocks, including a semiconductor play on fire.


Mylan CEO to testify at drug pricing hearing

CNBC's Meg Tirrell reports Heather Bresch will be under fire today when she heads to Capitol Hill to face questions about raising the price of the company's life-saving EpiPens.